Loading...
Market
Which of the following will be the biggest barrier to the widespread adoption of BlueBird Bio's gene therapy for sickle cell disease?
2
Resolution / Starting Odds
Cost • 25%
Insurance Coverage • 25%
Availability of Treatment Centers • 25%
Patient Awareness • 25%
Analysis and reports from healthcare industry experts
Story
12-Year-Old Kendric Cromer Receives $2.2 Million Gene Therapy for Sickle Cell Disease
Sep 16, 2024, 11:50 PM
Kendric Cromer, a 12-year-old boy, has become one of the first children to be treated with a newly approved gene therapy for sickle cell disease. This treatment, developed by BlueBird Bio, offers hope for a cure and a future free from the excruciating pain that has characterized his life. However, the high cost of the treatment, priced at $2.2 million, poses significant challenges. Insurers are hesitant to cover the expense, and hospitals are wary of the financial burden. The approval of this gene therapy by the FDA marks a significant milestone, but accessibility remains a critical issue for many patients. Deepak Srivastava highlights the broader issue of how to pay for breakthrough cures.
View original story
Similar markets
Cost • 25%
Regulatory approvals • 25%
Manufacturing capacity • 25%
Public awareness • 25%
Less than $500,000 • 25%
$500,000 to $750,000 • 25%
$750,000 to $1,000,000 • 25%
More than $1,000,000 • 25%
Cost • 25%
Distribution • 25%
Regulatory approval • 25%
Adherence • 25%
Cost of the drug • 25%
Distribution and accessibility issues • 25%
Lack of awareness and education • 25%
Regulatory hurdles • 25%
Safety warning update • 25%
Clinical trial halt • 25%
No action • 25%
Other action • 25%
Improved survival rates • 25%
Increased cancer rates • 25%
Stable condition • 25%
Other • 25%
CRISPR Therapeutics • 25%
Intellia Therapeutics • 25%
Beam Therapeutics • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Cost • 25%
Infrastructure • 25%
Regulatory approval • 25%
Lack of awareness • 25%